Cost-effectiveness of screening and treating anal pre-cancerous lesions among gay, bisexual and other men who have sex with men living with HIV

[1]  J. Palefsky,et al.  Treatment of Anal High-Grade Squamous Intraepithelial Lesions to Prevent Anal Cancer. , 2022, The New England journal of medicine.

[2]  A. Devine,et al.  Lifetime Cost of HIV Management in Australia: An Economic Model , 2021, Social Science Research Network.

[3]  P. Tekkis,et al.  Evaluating the efficacy of treatment options for anal intraepithelial neoplasia: a systematic review , 2020, International Journal of Colorectal Disease.

[4]  E. Stier,et al.  A meta‐analysis of anal cancer incidence by risk group: Toward a unified anal cancer risk scale , 2020, International journal of cancer.

[5]  S. Garland,et al.  The Natural History of Anal High-grade Squamous Intraepithelial Lesions in Gay and Bisexual Men. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  W. Quint,et al.  Cancer Risk Stratification of Anal Intraepithelial Neoplasia in Human Immunodeficiency Virus–Positive Men by Validated Methylation Markers Associated With Progression to Cancer , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  F. Bray,et al.  Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020-99: a modelling study. , 2019, The Lancet. Oncology.

[8]  N. Paracha,et al.  Systematic review of health state utility values in metastatic non-small cell lung cancer with a focus on previously treated patients , 2018, Health and Quality of Life Outcomes.

[9]  J. Chhatwal,et al.  Management of precancerous anal intraepithelial lesions in human immunodeficiency virus–positive men who have sex with men: Clinical effectiveness and cost‐effectiveness , 2017, Cancer.

[10]  S. Franceschi,et al.  Human papillomavirus types from infection to cancer in the anus, according to sex and HIV status: a systematic review and meta-analysis , 2017, The Lancet. Infectious diseases.

[11]  S. Garland,et al.  The performance of human papillomavirus biomarkers in predicting anal high-grade squamous intraepithelial lesions in gay and bisexual men , 2017, AIDS.

[12]  S. Garland,et al.  Prevalence and risk factors associated with high-grade anal squamous intraepithelial lesions (HSIL)-AIN2 and HSIL-AIN3 in homosexual men , 2016, Papillomavirus research.

[13]  S. Vavricka,et al.  Presenting symptoms predict local staging of anal cancer: a retrospective analysis of 86 patients , 2016, BMC Gastroenterology.

[14]  J. Kaldor,et al.  Cost-effectiveness of screening for anal cancer using regular digital ano-rectal examinations in men who have sex with men living with HIV , 2016, Journal of the International AIDS Society.

[15]  A. Kneebone,et al.  Implementing Intensity-modulated Radiotherapy with Simultaneous Integrated Boost for Anal Cancer: 3 Year Outcomes at Two Sydney Institutions. , 2015, Clinical oncology (Royal College of Radiologists (Great Britain)).

[16]  Karen E Bremner,et al.  A Review and Meta-analysis of Colorectal Cancer Utilities , 2014, Medical decision making : an international journal of the Society for Medical Decision Making.

[17]  J. Debus,et al.  Efficacy and toxicity of chemoradiation in patients with anal cancer - a retrospective analysis , 2014, Radiation oncology.

[18]  S. Garland,et al.  The Study of the Prevention of Anal Cancer (SPANC): design and methods of a three-year prospective cohort study , 2013, BMC Public Health.

[19]  M. Dijkgraaf,et al.  Comparison of imiquimod, topical fluorouracil, and electrocautery for the treatment of anal intraepithelial neoplasia in HIV-positive men who have sex with men: an open-label, randomised controlled trial. , 2013, The Lancet. Oncology.

[20]  David P. Wilson,et al.  Projected Demographic Profile of People Living with HIV in Australia: Planning for an Older Generation , 2012, PloS one.

[21]  H. Jessen,et al.  HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. , 2011, The New England journal of medicine.

[22]  C. Czoski-Murray,et al.  Cost-effectiveness of screening high-risk HIV-positive men who have sex with men (MSM) and HIV-positive women for anal cancer. , 2010, Health technology assessment.

[23]  J. Palefsky,et al.  Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions , 2009, International journal of cancer.

[24]  S. Franceschi,et al.  Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: A meta‐analysis , 2009, International journal of cancer.

[25]  J. Karnon,et al.  Cost-utility analysis of screening high-risk groups for anal cancer. , 2008, Journal of public health.

[26]  J. Raftery.  Paying for costly pharmaceuticals: regulation of new drugs in Australia, England and New Zealand , 2008, The Medical journal of Australia.

[27]  J. Brazier,et al.  The Estimation of a Preference-Based Measure of Health From the SF-12 , 2004, Medical care.

[28]  J. Brazier,et al.  The estimation of a preference-based measure of health from the SF-36. , 2002, Journal of health economics.

[29]  C. Moore,et al.  Rates of combination antiretroviral treatment change in Australia, 1997–2000 , 2002 .

[30]  M. Weinstein,et al.  The clinical effectiveness and cost-effectiveness of screening for anal squamous intraepithelial lesions in homosexual and bisexual HIV-positive men. , 1999, JAMA.

[31]  C. Sherbourne,et al.  The MOS 36-Item Short-Form Health Survey (SF-36) , 1992 .

[32]  A. Harris,et al.  Cost-Effectiveness Analysis and the Consistency of Decision Making , 2012, PharmacoEconomics.

[33]  Australian Hiv Observational Database.  Rates of combination antiretroviral treatment change in Australia, 1997-2000. , 2002, HIV medicine.

[34]  A. Harris,et al.  Cost-effectiveness analysis and the consistency of decision making: evidence from pharmaceutical reimbursement in australia (1991 to 1996). , 2001, PharmacoEconomics.

[35]  Ware J.E.Jr.,et al.  THE MOS 36- ITEM SHORT FORM HEALTH SURVEY (SF- 36) CONCEPTUAL FRAMEWORK AND ITEM SELECTION , 1992 .

[36]  P. Feros.  Pharmaceutical benefits scheme. , 1986, The Medical journal of Australia.